Valid prognostic studies can assist in answering these types of questions, and they assist in weighing the various factors that may contribute to specific outcomes. You may ask, "What is the prognosis for my patient to return home versus a rehabilitation facility at discharge?" or "What are the odds that this intervention will benefit my patient's independent ambulation?" Many factors influence the answers to prognostic questions such as the severity of the patient's problem, gender, age, home environment, and co-morbidities. For example, a patient may ask, "Will I be able to ski after back surgery?" or "When can I expect to go back to work?" Prognostic questions may also guide discharge planning. Prognostic questions may be about the impact of a disease or event on a patient's long-term outcome. Abstract 270.Patients, families, and physical therapists have many questions about prognosis. Dynamic Imaging and Tracer Kinetic Modeling of 18F-flutemetamol PET for ATTR Cardiac Amyloidosis Patients. "Using parametric modeling to fully quantify volume of distribution may provide clinicians with a more accurate and robust method for assessing the presence and progression of amyloid plaques in the myocardium, ultimately improving patient care."Ĭlick here for more coverage of SNMMI 2023. “These findings suggest that commonly employed semiquantitative methodologies, such as standardized uptake values used for 18F-FDG, are notoptimal for 18F-flutemetamol," Liu said in a statement. The Logan plot best identified the volume of distribution parameter from the first 30-minutes of dynamic scan (mean V T values, 2.35 ± 0.32 ( P =.01), 10.1% ± 5.5% lower than 60-minute data) as a quantitative parameter that could potentially improve diagnosis and evaluation of treatment effect in this patient population.
The mean V T values of the six patients was 2.61 ± 0.47 with plasma metabolite correction and population-based whole blood-to-plasma ratio correction, which was 118% ± 30% higher than those without corrections. Liu and colleagues found that the 2T reversible model best quantified the kinetics of the PET tracer, with the V T values generated by the 2T reversible compartmental model consistent with V T values calculated by the Logan plot ( P =.99). Parametric images of the the equilibrium myocardium to plasma ratio ( V T) were then generated. They examined both Patlak and Logan plots and tested one-tissue (1T), two-tissue (2T) reversible, and 2T irreversible compartmental models with blood volume estimation. Population-based whole blood-to-plasma ratio correction and plasma metabolite correction were derived from a previous study. They tested various compartmental models against 34 reconstructed dynamic images that included image-derived input functions and myocardium time activity curves. Liu and colleagues studied data from six patients with ATTR cardiac amyloidosis who underwent one hour of dynamic PET/CT after receiving 18F-flutemetamol tracer via bolus. Current methods that utilize static data analysis are limited due to time constraints related to tracer washout from the myocardium, resulting in a limited or incomplete readout.
Researchers led by Qiong Liu, a PhD student at Yale University, set out to determine a fully quantitative model to better measure myocardial uptake of 18F-flutemetamol, a tracer that has shown promise to detect ATTR cardiac amyloidosis in PET imaging. A new kinetic model for a PET imaging tracer may help significantly improve both the diagnosis of and treatment response for patients with transthyretin (ATTR) cardiac amyloidosis, according to research presented at the 2023 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago.
0 kommentar(er)
